Advertisement
HBIO vs TELA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a StrongBuy and TELA is a Hold.
HBIO sees its Stochastic Oscillator ascending out of oversold territory
On October 20, 2026, the Stochastic Oscillator for HBIO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In 49 of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in 161 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for HBIO moved out of overbought territory on October 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 16 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HBIO as a result. In 92 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for HBIO turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 46 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
HBIO broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. HBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.210) is normal, around the industry mean (4.952). P/E Ratio (-3.691) is within average values for comparable stocks, (36.644). HBIO's Projected Growth (PEG Ratio) (14.400) is slightly higher than the industry average of (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.410) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
TELA's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for TELA moved out of overbought territory on September 24, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 18 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TELA turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TELA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
TELA broke above its upper Bollinger Band on September 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 68 cases where TELA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on TELA as a result. In 78 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +12.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where TELA advanced for three days, in 174 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 112 of 136 cases where TELA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.073) is normal, around the industry mean (2.923). P/E Ratio (-1.403) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.782) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TELA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TELA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
HBIO | TELA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 36 | 39 | |
P/E GROWTH RATING 1..100 | 83 | 88 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TELA's Valuation (31) in the null industry is significantly better than the same rating for HBIO (98) in the Biotechnology industry. This means that TELA’s stock grew significantly faster than HBIO’s over the last 12 months.
TELA's Profit vs Risk Rating (100) in the null industry is in the same range as HBIO (100) in the Biotechnology industry. This means that TELA’s stock grew similarly to HBIO’s over the last 12 months.
HBIO's SMR Rating (98) in the Biotechnology industry is in the same range as TELA (100) in the null industry. This means that HBIO’s stock grew similarly to TELA’s over the last 12 months.
HBIO's Price Growth Rating (36) in the Biotechnology industry is in the same range as TELA (39) in the null industry. This means that HBIO’s stock grew similarly to TELA’s over the last 12 months.
HBIO's P/E Growth Rating (83) in the Biotechnology industry is in the same range as TELA (88) in the null industry. This means that HBIO’s stock grew similarly to TELA’s over the last 12 months.
| HBIO | TELA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 72% | about 1 month ago 76% |
| Declines ODDS (%) | 15 days ago 87% | 4 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 71% | 7 days ago 83% |
| Aroon ODDS (%) | N/A | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HBIO’s FA Score shows that 0 FA rating(s) are green while TELA’s FA Score has 1 green FA rating(s).
- HBIO’s FA Score: 0 green, 5 red.
- TELA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HBIO’s TA Score shows that 2 TA indicator(s) are bullish while TELA’s TA Score has 4 bullish TA indicator(s).
- HBIO’s TA Score: 2 bullish, 5 bearish.
- TELA’s TA Score: 4 bullish, 4 bearish.
Price Growth
HBIO (@Pharmaceuticals: Other) experienced а +4.17% price change this week, while TELA (@Medical/Nursing Services) price change was -1.37% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
Reported Earning Dates
HBIO is expected to report earnings on Nov 05, 2026.
TELA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.74% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
HBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.
| Ticker / NAME | Correlation To HBIO | 1D Price Change % | ||
|---|---|---|---|---|
| HBIO | 100% | +1.80% | ||
| IRMD - HBIO | 46% Loosely correlated | -0.49% | ||
| A - HBIO | 37% Loosely correlated | +2.74% | ||
| RVTY - HBIO | 36% Loosely correlated | +0.38% | ||
| MTD - HBIO | 35% Loosely correlated | +2.69% | ||
| NEOG - HBIO | 34% Loosely correlated | +0.60% | ||
More | ||||
TELA and
Correlation & Price change
A.I.dvisor tells us that TELA and BAX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TELA and BAX's prices will move in lockstep.
| Ticker / NAME | Correlation To TELA | 1D Price Change % | ||
|---|---|---|---|---|
| TELA | 100% | -0.92% | ||
| BAX - TELA | 28% Poorly correlated | +0.78% | ||
| AMIX - TELA | 27% Poorly correlated | -1.53% | ||
| HBIO - TELA | 27% Poorly correlated | +1.80% | ||
| TFX - TELA | 27% Poorly correlated | -0.57% | ||
| AZTA - TELA | 26% Poorly correlated | +2.88% | ||
More | ||||